Kurzfassung

The promising clinical results obtained with engineered T cells, including adoptive cell transfer therapy, call for further advancements to facilitate and broaden their applicability. We propose a broad and unique approach to engineer alternative T cell populations derived from different hematopoietic stem cell sources (bone marrow, peripheral blood, umbilical cord blood and induced pluripotent stem cell) and to compare in parallel their efficacy and safety towards the...The promising clinical results obtained with engineered T cells, including adoptive cell transfer therapy, call for further advancements to facilitate and broaden their applicability. We propose a broad and unique approach to engineer alternative T cell populations derived from different hematopoietic stem cell sources (bone marrow, peripheral blood, umbilical cord blood and induced pluripotent stem cell) and to compare in parallel their efficacy and safety towards the prospect for true off-the-shelf, genetically enhanced, histocompatible cell therapy products.
 » weiterlesen» einklappen